Fengyi Liu

ORCID: 0009-0009-7289-836X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Healthcare and Venom Research
  • Acupuncture Treatment Research Studies
  • Traditional Chinese Medicine Studies
  • Inflammasome and immune disorders
  • Cancer Immunotherapy and Biomarkers
  • interferon and immune responses
  • Advanced Breast Cancer Therapies
  • HER2/EGFR in Cancer Research
  • Fatty Acid Research and Health
  • Iron Metabolism and Disorders
  • Diet and metabolism studies
  • Pharmacology and Obesity Treatment
  • Metabolism and Genetic Disorders
  • Folate and B Vitamins Research
  • Cancer, Stress, Anesthesia, and Immune Response
  • Chronic Lymphocytic Leukemia Research
  • Pharmacological Effects of Natural Compounds
  • Pancreatic function and diabetes
  • Liver Disease Diagnosis and Treatment
  • Hippo pathway signaling and YAP/TAZ
  • Cancer Treatment and Pharmacology

Harbin Medical University
2023-2024

First Affiliated Hospital of Harbin Medical University
2023-2024

Pfizer (United States)
2024

Heilongjiang University of Chinese Medicine
2023

Abstract Programmed death receptor-1 (PD-1) inhibitors are ineffective against microsatellite-stable (MSS) colorectal cancer. Electroacupuncture (EA) has oncosuppressive and immunomodulatory properties. Here, we investigated the antitumor effects of EA explored feasibility combined with anti–PD-1 in MSS Results showed that exerted its effect an intensity-specific manner, moderate-intensity (1.0 mA) induced maximal tumor inhibition. enhanced immune responses by increasing lymphocytes granzyme...

10.1158/2326-6066.cir-23-0309 article EN Cancer Immunology Research 2023-11-13

PF-07220060 is a novel potent oral CDK4i with significant sparing of CDK6. Preliminary safety and dose escalation data from this phI/IIastudy were previously presented. Here we report updated efficacy in pts HR+/HER2− mBC, who progressed on prior CDK4/6i ET, treated + ET. This study advanced solid tumors was enriched for mBC received ≥2 lines treatment including ET CDK4/6i. Prior fulvestrant chemotherapy allowed. Study objectives to assess safety, tolerability, antitumor activity alone...

10.1016/j.esmoop.2024.103206 article EN cc-by-nc-nd ESMO Open 2024-05-01

<div>Abstract<p>Programmed death receptor-1 (PD-1) inhibitors are ineffective against microsatellite-stable (MSS) colorectal cancer. Electroacupuncture (EA) has oncosuppressive and immunomodulatory properties. Here, we investigated the antitumor effects of EA explored feasibility combined with anti–PD-1 in MSS Results showed that exerted its effect an intensity-specific manner, moderate-intensity (1.0 mA) induced maximal tumor inhibition. enhanced immune responses by increasing...

10.1158/2326-6066.c.7005676.v1 preprint EN 2024-01-03

<div>Abstract<p>Programmed death receptor-1 (PD-1) inhibitors are ineffective against microsatellite-stable (MSS) colorectal cancer. Electroacupuncture (EA) has oncosuppressive and immunomodulatory properties. Here, we investigated the antitumor effects of EA explored feasibility combined with anti–PD-1 in MSS Results showed that exerted its effect an intensity-specific manner, moderate-intensity (1.0 mA) induced maximal tumor inhibition. enhanced immune responses by increasing...

10.1158/2326-6066.c.7005676 preprint EN 2024-01-03

<title>Abstract</title> Background: Evidence regarding the health effects of saturated fatty acids (SFAs), monounsaturated (MUFAs), and total polyunsaturated (PUFAs) is controversial. Our objective was to explore associations between serum-free mortality among cancer survivors. Methods: The study included 6,575 participants with or without diagnosis aged 20 years older a who were recruited before December 2014 followed up through 31, 2019. Hazard ratios (HRs) 95% confidence intervals (CIs)...

10.21203/rs.3.rs-5372142/v1 preprint EN cc-by Research Square (Research Square) 2024-12-02
Coming Soon ...